Standout Papers

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lym... 2018 2026 2020 2023 370
  1. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial (2018)
    Carol Moreno, Richard Greil et al. The Lancet Oncology

Immediate Impact

1 from Science/Nature 57 standout
Sub-graph 1 of 22

Citing Papers

Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
2025 Standout
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2025 Standout
4 intermediate papers

Works of Bertrand Anz being referenced

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
2022
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
2018 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Bertrand Anz 457 168 97 380 20 523
Владимир Стругов 450 123 61 381 12 469
Andrzej Pluta 362 179 90 281 23 497
Maurice Navarro 350 90 66 316 13 492
Ulrike Söling 433 119 76 372 16 506
Manit Munshi 516 175 69 452 40 603
Manuela A. Bergmann 543 98 54 490 11 573
Marie‐Sarah Dilhuydy 365 133 88 322 29 590
K Merkle 476 146 177 435 23 649
Michael Gulrajani 529 202 109 399 18 647
Yuh Shan Lee 372 93 113 344 17 510

All Works

Loading papers...

Rankless by CCL
2026